RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: A systematic review
Brennan, V., Mauskopf, J., Colosia, A., Copley-Merriman, C., Hass, B., & Palencia, R. (2015). Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: A systematic review. Expert Review of Pharmacoeconomics & Outcomes Research, 15(1), 111-123. https://doi.org/10.1586/14737167.2015.965152
A systematic review identified studies eliciting utility decrements from myocardial infarction (MI) and stroke in patients with Type 2 diabetes mellitus (T2DM) and examined their use in economic models of new diabetes treatments. In 16 utility studies in patients with T2DM, utility decrements in the first year ranged from 0.017 to 0.226 for MI and from 0.034 to 0.590 for stroke. Sixteen of 19 economic evaluations of new treatments for T2DM included utility decrements for an MI and/or stroke from one of the 16 utility studies. Decrements for MI ranged from 0.012 to 0.180 in the first year. Decrements for stroke ranged from 0.044 to 0.690 in the first year. Utility studies in patients with T2DM provide little information about changes in utility decrements by time since the event and by disease severity. Cost-effectiveness studies do not always indicate how these values were used in the analysis
